USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
PT2314629E
(en)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Recombinant production of mixtures of antibodies
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP5953303B2
(en)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
Antibodies with modified isoelectric points
|
HUE038305T2
(en)
|
2010-11-17 |
2018-10-29 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
WO2012073985A1
(en)
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
Cytotoxicity-inducing therapeutic agent
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
BR112013020338A2
(en)
|
2011-02-28 |
2016-10-18 |
Hoffmann La Roche |
monovalent antigen binding protein, pharmaceutical composition, use of monovalent antigen binding protein, method for treating a patient in need of therapy, method for preparing a monovalent antigen binding protein, nucleic acid, vector and cell hostess
|
AU2012235758B2
(en)
*
|
2011-03-25 |
2015-05-07 |
Ichnos Sciences SA |
Hetero-dimeric immunoglobulins
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013065708A1
(en)
|
2011-10-31 |
2013-05-10 |
中外製薬株式会社 |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
HUE045944T2
(en)
|
2012-04-20 |
2020-02-28 |
Merus Nv |
Methods and means for the production of heterodimeric ig-like molecules
|
JP6351572B2
(en)
*
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Heteromultimeric constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
KR20150076172A
(en)
|
2012-09-25 |
2015-07-06 |
그렌마크 파머수티칼스 에스. 아. |
Purification of Hetero-dimeric Immunoglobulins
|
WO2014051433A1
(en)
|
2012-09-27 |
2014-04-03 |
Merus B.V. |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
EP2904093B1
(en)
|
2012-10-03 |
2019-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
US9562110B2
(en)
*
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
US10077298B2
(en)
*
|
2012-11-28 |
2018-09-18 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN111138543A
(en)
*
|
2013-03-15 |
2020-05-12 |
Xencor股份有限公司 |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
PT3050896T
(en)
|
2013-09-27 |
2021-08-24 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
MY176522A
(en)
*
|
2013-11-04 |
2020-08-13 |
Ichnos Sciences SA |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
CN105980409B
(en)
|
2013-11-27 |
2023-07-18 |
酵活生物制药有限公司 |
Bispecific antigen binding constructs targeting HER2
|
HUE050156T2
(en)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-cd3 antibodies and methods of use
|
SG10201913289TA
(en)
|
2014-02-28 |
2020-02-27 |
Merus Nv |
Antibody that binds erbb-2 and erbb-3
|
JP6771385B2
(en)
|
2014-02-28 |
2020-10-21 |
メルス ナムローゼ フェンノートシャップ |
Bispecific antibody and pharmaceutical composition
|
SG10202008629XA
(en)
*
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
SG11201608054YA
(en)
|
2014-04-02 |
2016-10-28 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
UA117289C2
(en)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Multispecific antibodies
|
IL286367B2
(en)
|
2014-05-02 |
2023-03-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
WO2015173756A2
(en)
|
2014-05-16 |
2015-11-19 |
Pfizer Inc. |
Bispecific antibodies
|
CA2946503C
(en)
*
|
2014-05-28 |
2022-11-22 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
EP3172325B1
(en)
|
2014-07-22 |
2023-06-28 |
The University of Notre Dame du Lac |
Molecular constructs and uses thereof
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
GB201414823D0
(en)
*
|
2014-08-20 |
2014-10-01 |
Argen X Bv |
Multispecific antibodies
|
JP6886398B2
(en)
|
2014-09-12 |
2021-06-16 |
ジェネンテック, インコーポレイテッド |
ANTI-CLL-1 antibody and immune complex
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
MA41480A
(en)
*
|
2014-10-17 |
2017-12-19 |
Glenmark Pharmaceuticals Sa |
ANTIBODIES BOUND TO CCR6 AND THEIR USES
|
MA40894A
(en)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
LT3223845T
(en)
|
2014-11-26 |
2021-08-25 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
EA037065B1
(en)
|
2014-11-26 |
2021-02-01 |
Ксенкор, Инк. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US20170355779A1
(en)
*
|
2014-11-27 |
2017-12-14 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
MA41375A
(en)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
CN116063543A
(en)
*
|
2015-04-24 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
Multispecific antigen-binding proteins
|
JP2018526972A
(en)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
Anti-CD3 antibody and method of use
|
CN107847568B
(en)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
anti-CLL-1 antibodies and methods of use
|
HRP20231134T1
(en)
|
2015-06-16 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
KR102095096B1
(en)
|
2015-08-26 |
2020-03-30 |
바이슨 테라퓨틱스 인크. |
Multispecific antibody platforms and related methods
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
EP3150636A1
(en)
*
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
CN108290958B
(en)
*
|
2015-10-02 |
2021-12-28 |
豪夫迈·罗氏有限公司 |
Multispecific antibodies
|
CN108283001B
(en)
|
2015-10-08 |
2022-08-19 |
酵活有限公司 |
Antigen binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
US11939394B2
(en)
|
2015-10-23 |
2024-03-26 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
CN106883297B
(en)
*
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
CH3 domain-based heterodimer molecule, preparation method and application thereof
|
CN108779182A
(en)
|
2015-12-28 |
2018-11-09 |
麻省理工学院 |
Bispecific antibody and application thereof with constant region mutation
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
CN116284428A
(en)
|
2016-03-25 |
2023-06-23 |
拜奥穆尼克斯制药 |
Molecules that bind CD38 and PD-L1
|
JP7258556B2
(en)
*
|
2016-04-28 |
2023-04-17 |
ビオミューネクス・ファルマシューティカル |
Bispecific antibodies targeting EGFR and HER2
|
IL263211B2
(en)
|
2016-05-23 |
2023-09-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
KR102098919B1
(en)
*
|
2016-07-19 |
2020-04-23 |
(주) 아이벤트러스 |
Bispecific protein and methods of preparation thereof
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EA201990285A1
(en)
*
|
2016-09-29 |
2019-12-30 |
Бейджин Ханми Фармасьютикал Ко., Лтд. |
HETERODIMERIC IMMUNOGLOBULIN STRUCTURES AND METHODS FOR PRODUCING THEM
|
MX2019004327A
(en)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments.
|
MX2019005438A
(en)
|
2016-11-15 |
2019-08-16 |
Genentech Inc |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies.
|
EA201990894A9
(en)
|
2016-11-18 |
2019-11-27 |
|
ANTI-PD-1 / ANTI-HER2 HETERODIMERIC BASPECIFIC ANTIBODY WITH NATURAL ANTIBODY STRUCTURE AND METHOD FOR ITS PRODUCTION
|
WO2018129255A1
(en)
|
2017-01-06 |
2018-07-12 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
JP7288401B2
(en)
*
|
2017-01-10 |
2023-06-07 |
プレシゲン,インコーポレイテッド |
Modulation of polypeptide expression via a novel gene switch expression system
|
JP2020506971A
(en)
|
2017-02-08 |
2020-03-05 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Multispecific binding proteins for the activation of natural killer cells and their therapeutic use for treating cancer
|
CN110461361A
(en)
*
|
2017-02-10 |
2019-11-15 |
蜻蜓治疗公司 |
In conjunction with the albumen of BCMA, NKG2D and CD16
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
CN110944661A
(en)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
HER2, NKG2D and CD16 binding proteins
|
KR20190141154A
(en)
|
2017-03-27 |
2019-12-23 |
바이오뮤넥스 파마슈티컬스 |
Stable Multispecific Antibodies
|
BR112019020508A2
(en)
|
2017-03-31 |
2020-08-04 |
Merus N.V. |
bispecific antibodies binding to erbb-2 and erbb3 for use in the treatment of cells that have an nrg1 fusion gene
|
CA3059769A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
MA49517A
(en)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING
|
US11773170B2
(en)
|
2017-08-09 |
2023-10-03 |
Merus N.V. |
Antibodies that bind EGFR and cMET
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to bcma and uses thereof
|
EP3446710A1
(en)
|
2017-08-25 |
2019-02-27 |
Glenmark Pharmaceuticals S.A. |
Methods of inactivating viral contaminants
|
WO2019057124A1
(en)
|
2017-09-22 |
2019-03-28 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific cd3/cd19 polypeptide complexes
|
US11845796B2
(en)
|
2017-09-22 |
2023-12-19 |
WuXi Biologics Ireland Limited |
Bispecific polypeptide complexes
|
BR112020005834A2
(en)
*
|
2017-09-29 |
2020-09-24 |
Chugai Seiyaku Kabushiki Kaisha |
multispecific antigen binding molecule having blood clotting factor viii cofactor function (fviii) replacement activity, and pharmaceutical formulation containing said molecule as an active ingredient
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
WO2019153200A1
(en)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
|
AR115360A1
(en)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
ANTIGEN BINDING MOLECULES AND METHODS OF USE
|
JP2021512630A
(en)
|
2018-02-08 |
2021-05-20 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Antibody variable domain targeting NKG2D receptor
|
CA3090878A1
(en)
|
2018-02-11 |
2019-08-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
EP3802605A1
(en)
|
2018-06-01 |
2021-04-14 |
Compugen Ltd. |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
CR20210047A
(en)
|
2018-07-02 |
2021-05-21 |
Amgen Inc |
ANTI-STEAP1 ANTIGEN BINDING PROTEIN
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
WO2020053301A1
(en)
|
2018-09-11 |
2020-03-19 |
Ichnos Sciences S.A. |
Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
|
US20220034899A1
(en)
|
2018-09-25 |
2022-02-03 |
Ichnos Sciences S.A. |
Antibody quantification in biological samples
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
MA53862A
(en)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
FC FUSION PROTEINS OF IL-15/IL-15RALPHA TARGETTING PD-1 AND USES IN COMBINATION THERAPIES INVOLVING THE SAME
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
JP2022521937A
(en)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Antibody molecules that bind to NKp30 and their use
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022521750A
(en)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Multifunctional molecule that binds to calreticulin and its use
|
JP2022521751A
(en)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Anti-TCR antibody molecule and its use
|
JP2022522662A
(en)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Multifunctional molecules that bind to T cells and their use for treating autoimmune disorders
|
MA55089A
(en)
|
2019-02-26 |
2022-01-05 |
Janssen Biotech Inc |
COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES
|
KR20210134725A
(en)
|
2019-03-01 |
2021-11-10 |
젠코어 인코포레이티드 |
Heterodimeric Antibodies that Bind to ENPP3 and CD3
|
US20220177582A1
(en)
|
2019-03-13 |
2022-06-09 |
Ichnos Sciences SA |
Non-consensus glycosylation of bispecific antibodies
|
US20220227827A1
(en)
*
|
2019-03-25 |
2022-07-21 |
Dingfu Biotarget Co., Ltd. |
Proteinaceous heterodimer and use thereof
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
TW202128757A
(en)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
CN114981297A
(en)
|
2019-12-23 |
2022-08-30 |
戴纳立制药公司 |
Proteinogenin variants
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
MX2022015509A
(en)
|
2020-06-12 |
2023-02-23 |
Ichnos Sciences SA |
Antibody formulation diluent.
|
IL300666A
(en)
|
2020-08-19 |
2023-04-01 |
Xencor Inc |
Anti-cd28 compositions
|
JP2023539645A
(en)
|
2020-08-26 |
2023-09-15 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Antibody molecules that bind to NKP30 and uses thereof
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
EP4204450A2
(en)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP4211165A1
(en)
|
2020-09-14 |
2023-07-19 |
Ichnos Sciences SA |
Antibodies that bind to il1rap and uses thereof
|
JP2023542907A
(en)
|
2020-09-18 |
2023-10-12 |
イシュノス サイエンシズ ソシエテ アノニム |
CD47-CD38 bispecific antibody
|
KR20230156079A
(en)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Heterodimeric antibody binding to CD3 and CLDN6
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
WO2023052556A1
(en)
|
2021-09-30 |
2023-04-06 |
Ichnos Sciences SA |
Methods of inactivating viral contaminants with a mixture of solvent and detergent
|
WO2023137322A1
(en)
*
|
2022-01-11 |
2023-07-20 |
Adimab, Llc |
Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
|
WO2023213998A1
(en)
|
2022-05-06 |
2023-11-09 |
Ichnos Sciences SA |
Cd3/bcma/cd38 trispecific antibodies
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|